Mously LeBlanc1, Margaret Stineman2, Angela DeMichele3, Carrie Stricker4, Jun J Mao5. 1. Department of Physical Medicine and Rehabilitation, University of Pennsylvania Health System, Philadelphia, PA; Abramson Cancer Center, University of Pennsylvania Health System, Philadelphia, PA. Electronic address: mously.leblanc@uphs.upenn.edu. 2. Department of Physical Medicine and Rehabilitation, University of Pennsylvania Health System, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Health System, Philadelphia, PA. 3. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Health System, Philadelphia, PA; Abramson Cancer Center, University of Pennsylvania Health System, Philadelphia, PA. 4. Abramson Cancer Center, University of Pennsylvania Health System, Philadelphia, PA. 5. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Health System, Philadelphia, PA; Abramson Cancer Center, University of Pennsylvania Health System, Philadelphia, PA; Department of Family Medicine and Community Health, University of Pennsylvania Health System, Philadelphia, PA.
Abstract
OBJECTIVE: To validate the QuickDASH as a patient-reported outcome measure for assessing upper extremity disability in breast cancer survivors. DESIGN: Large cross-sectional survey. SETTING: Ambulatory care center at a university hospital. PARTICIPANTS: Postmenopausal women (N=150) with stage I to III hormone receptor-positive breast cancer currently taking a third-generation aromatase inhibitor. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURE: QuickDASH, an 11-item self-administered questionnaire, assesses global arm function over the past 7 days. RESULTS: Of 150 surveys, 148 (99%) were scorable. The factor analysis demonstrated 1 factor with an eigenvalue of 6.7, which explains 61% of variance. The score was reliable with a Cronbach alpha of .93. The test-retest reliability was .78 over 2 weeks. The mean QuickDASH score ± SD for all patients was 19±19. Those with upper extremity arthralgias reported higher QuickDASH scores than controls without pain (26 vs 12, P=.001). Those with frozen shoulder pain also reported higher QuickDASH scores than controls without pain (37 vs 15, P=.001). CONCLUSIONS: The QuickDASH instrument is a convenient, reliable, and valid patient-reported outcome measure to assess upper extremity disability in patients with breast cancer.
OBJECTIVE: To validate the QuickDASH as a patient-reported outcome measure for assessing upper extremity disability in breast cancer survivors. DESIGN: Large cross-sectional survey. SETTING: Ambulatory care center at a university hospital. PARTICIPANTS: Postmenopausal women (N=150) with stage I to III hormone receptor-positive breast cancer currently taking a third-generation aromatase inhibitor. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURE: QuickDASH, an 11-item self-administered questionnaire, assesses global arm function over the past 7 days. RESULTS: Of 150 surveys, 148 (99%) were scorable. The factor analysis demonstrated 1 factor with an eigenvalue of 6.7, which explains 61% of variance. The score was reliable with a Cronbach alpha of .93. The test-retest reliability was .78 over 2 weeks. The mean QuickDASH score ± SD for all patients was 19±19. Those with upper extremity arthralgias reported higher QuickDASH scores than controls without pain (26 vs 12, P=.001). Those with frozen shoulder pain also reported higher QuickDASH scores than controls without pain (37 vs 15, P=.001). CONCLUSIONS: The QuickDASH instrument is a convenient, reliable, and valid patient-reported outcome measure to assess upper extremity disability in patients with breast cancer.
Authors: Margaret L McNeely; Kristin L Campbell; Brian H Rowe; Terry P Klassen; John R Mackey; Kerry S Courneya Journal: CMAJ Date: 2006-07-04 Impact factor: 8.262
Authors: Jun J Mao; Carrie Stricker; Deborah Bruner; Sharon Xie; Marjorie A Bowman; John T Farrar; Brandon T Greene; Angela DeMichele Journal: Cancer Date: 2009-08-15 Impact factor: 6.860
Authors: Barbara A Springer; Ellen Levy; Charles McGarvey; Lucinda A Pfalzer; Nicole L Stout; Lynn H Gerber; Peter W Soballe; Jerome Danoff Journal: Breast Cancer Res Treat Date: 2010-02 Impact factor: 4.872
Authors: Gunjan Y Gandhi; M Hassan Murad; Akira Fujiyoshi; Rebecca J Mullan; David N Flynn; Mohamed B Elamin; Brian A Swiglo; William L Isley; Gordon H Guyatt; Victor M Montori Journal: JAMA Date: 2008-06-04 Impact factor: 56.272
Authors: Lorraine T Dean; Angela DeMichele; Mously LeBlanc; Alisa Stephens-Shields; Susan Q Li; Chris Colameco; Morgan Coursey; Jun J Mao Journal: Breast Cancer Res Treat Date: 2015-09-29 Impact factor: 4.872
Authors: Farkhondeh Jamshidi; Maryam Farzad; Joy C MacDermid; Azar Varahra; Seyed Ali Hosseini; Mojtaba Habibi Asgarabad Journal: Breast Cancer Date: 2022-03-01 Impact factor: 3.307
Authors: Elise M Gane; Steven M McPhail; Anna L Hatton; Benedict J Panizza; Shaun P O'Leary Journal: J Cancer Surviv Date: 2018-05-16 Impact factor: 4.442
Authors: Elizabeth A Chrischilles; Danielle Riley; Elena Letuchy; Linda Koehler; Joan Neuner; Cheryl Jernigan; Brian Gryzlak; Neil Segal; Bradley McDowell; Brian Smith; Sonia L Sugg; Jane M Armer; Ingrid M Lizarraga Journal: Breast Cancer Res Treat Date: 2019-03-09 Impact factor: 4.872
Authors: Ingrid M Lizarraga; Mary C Schroeder; Ismail Jatoi; Sonia L Sugg; Amy Trentham-Dietz; Laurel Hoeth; Elizabeth A Chrischilles Journal: Ann Surg Oncol Date: 2021-07-12 Impact factor: 5.344
Authors: Kevin T Liou; Ray Baser; Sally A D Romero; Jamie Green; Q Susan Li; Irene Orlow; Katherine S Panageas; Jun J Mao Journal: Medicine (Baltimore) Date: 2020-05-22 Impact factor: 1.817